Psychiatric Medication Prescribing Algorithm

General Principles

The American Academy of Child and Adolescent Psychiatry recommends treatment decisions should involve shared decision-making with the patient whenever possible, informing them about available treatment options, potential risks and benefits 1
Medication selection should be individualized based on current symptoms, patient preferences regarding side effects, efficacy, and route of administration 1, 2
The Lancet Psychiatry suggests treatment effectiveness should be assessed early, with a proactive approach when starting, switching, or augmenting medications 1, 2
Clear documentation of target symptoms, treatment response, and suspected side effects is essential for monitoring progress 2

The Journal of the American Academy of Child and Adolescent Psychiatry recommends confirming primary psychiatric diagnosis and identifying any comorbid conditions 3
Rule out medical conditions that may present with psychiatric symptoms 3
Assess for substance use disorders that may complicate treatment 1
Evaluate psychosocial stressors that may be mistaken for biological illness requiring medication 3

For schizophrenia, the Lancet Psychiatry recommends selecting antipsychotic based on side-effect profile and patient preference 2
If inadequate response after 4 weeks, switch to alternative antipsychotic with different pharmacodynamic profile 1, 2
For confirmed treatment-resistant schizophrenia, consider clozapine with concomitant metformin to attenuate weight gain 4, 2
For depression with psychotic features, combine antipsychotic with antidepressant 5
For bipolar disorder, use mood stabilizer (lithium, divalproex) or atypical antipsychotic for acute mania 6
For oppositional defiant disorder, first address comorbid conditions (e.g., ADHD, anxiety) with appropriate medications 6

Start with lower doses and titrate gradually based on response and tolerability 3
For antipsychotics, aim for the lowest effective dose that controls symptoms 1
For clozapine, titrate to achieve plasma levels of at least 350 ng/mL if response is inadequate at lower concentrations 4
Consider pharmacokinetic factors (age, gender, ethnicity, comorbidities) that may affect dosing 1

Before starting antipsychotics, obtain baseline BMI, waist circumference, blood pressure, HbA1c, glucose, lipids, prolactin, liver function, electrolytes, CBC, and ECG 7
Weekly for first 6 weeks, check BMI, waist circumference, and blood pressure 7
At 3 months and annually, repeat all baseline measures 7
For mood stabilizers, monitor serum levels, thyroid function, renal function, and electrolytes for lithium, and liver function, CBC, and drug levels for valproate 6

For metabolic side effects, offer lifestyle advice, consider metformin (500 mg daily, increased to 1g twice daily as tolerated) 7
For extrapyramidal symptoms, consider dose reduction or switch to medication with lower risk 7
For akathisia, consider dose reduction, switch to quetiapine/olanzapine, or add propranolol 7

Assess response after 4 weeks of treatment at adequate dose 1, 2
If inadequate response, consider dose adjustment 4, medication switch 2, augmentation strategies 5, or reassessment of diagnosis 3, 1

Mistaking behavioral reactions to psychosocial stressors as symptoms requiring medication 3
Unnecessarily complex medication regimens when psychosocial interventions may be more appropriate 3
Inadequate monitoring of side effects, particularly metabolic parameters 7
Premature discontinuation before adequate trial duration 3
Failure to reassess diagnosis when multiple medication trials are unsuccessful 1